Vandetanib Widespread Myths Vs. The Simple Evidence

Матеріал з HistoryPedia
Версія від 14:12, 4 червня 2017, створена Animal13neck (обговореннявнесок) (Створена сторінка: ""We compare the early and midterm outcomes of pulmonary thromboembolism (PTE) in patients with and without syncope in our single-center registry. Between Decem...)

(різн.) ← Попередня версія • Поточна версія (різн.) • Новіша версія → (різн.)
Перейти до: навігація, пошук

""We compare the early and midterm outcomes of pulmonary thromboembolism (PTE) in patients with and without syncope in our single-center registry. Between December 2006 and May 2013, 351 consecutive patients (mean age?=?60.21?��?16.91 Vandetanib cell line years, 55.3% male) with confirmed acute symptomatic PTE were divided in with and without syncope groups. Groups were compared in terms of the effect of syncope on 30-day mortality and adverse events, and mortality in a median follow-up time of 16.9 months. From 351 patients, 39 (11.1%) had syncope and 312 (88.9%) did not. Syncope group had less frequently chest pain (30.8% vs 51.4%; P value?=?0.015). Also, the rates of 30-day adverse events and mortality were 12.8% and 5.1% for the group with syncope, and 14.4% and 10.3% for the group without syncope, respectively, with no significant difference. At follow up, 65 patients died and mortality was 18.5% for 351 patients (5.1% in the group with syncope and 20.2% for the other group). After adjustment for confounding factors, the effect of syncope Selleck Verteporfin on 30-day adverse events and mortality remained non-significant and on the midterm mortality was significant, showing that the presence of syncope was associated with lower midterm mortality (P value?=?0.038). Among PTE patients in our registry, 11.1% presented with syncope. Relationship between syncope and 30-day adverse events and mortality remained non-significant after adjustments for other factors. However, in midterm follow up, patients with syncope were significantly at decreased risk of mortality compared to those without syncope. ""Recent studies have revealed a potential relationship between the presence of ground glass opacity (GGO) on regular computerized tomography (CT) and adenocarcinomas. To investigate features of pre-invasive lung adenocarcinoma lesions on thin-section CT. We evaluated 59 cases of atypical adenomatous hyperplasia (AAH) and 35 cases of adenoma in situ (AIS) confirmed by histopathology. Comparison of thin-section CT features, such as size, shape, margin, internal characteristics, and adjacent structures of pre-invasive lesions were analyzed. Lesions were further classified to pure ground glass opacity (pGGO) and mixed ground glass opacity (mGGO). Differences were analyzed Itraconazole using Chi-square or Fisher tests. There were significant differences in lobulation, spiculation, and bubble lucency between pGGO and mGGO (P??0.05). In the group of pGGO, AAH and AIS lesions did not differ significantly in size (P?>?0.05), while significant differences were found with respect to lobulation, spiculation, pleural indentation, and vascular morphological changes (P?